Glycosphingolipids (GSLs) are neoplastic and normal/ cancer stem cell markers and GSL/cholesterol-containing membrane rafts are increased in cancer cell plasma membranes. We define a novel means by which cancer cells can restrict tumor-associated GSL immunoreactivity. The GSL-cholesterol complex reorients GSL carbohydrate to a membrane parallel, rather than perpendicular conformation, largely unavailable for antibody recognition. Methyl-β-cyclodextrin cholesterol extraction of all primary human tumor frozen sections tested (ovarian, testicular, neuroblastoma, prostate, breast, colon, pheochromocytoma and ganglioneuroma), unmasked previously "invisible" membrane GSLs for immunodetection. In ovarian carcinoma, globotriaosyl ceramide (Gb 3 ), the GSL receptor for the antineoplastic Escherichia coli-derived verotoxin, was increased throughout the tumor. In colon carcinoma, Gb 3 detection was vastly increased within the neovasculature and perivascular stroma. In tumors considered Gb 3 negative (neuroblastoma, Leydig testicular tumor and pheochromocytoma), neovascular Gb 3 was unmasked. Tumorassociated GSL stage-specific embryonic antigen (SSEA)-1, SSEA-3, SSEA-4 and globoH were unmasked according to tumor: SSEA-1 in prostate/colon; SSEA-3 in prostate; SSEA-4 in pheochromocytoma/some colon tumors; globoH in prostate/some colon tumors. In colon, anti-SSEA-1 was tumor cell specific. Within the GSL-cholesterol complex, filipin-cholesterol binding was also reduced. These results may relate to the ill-defined benefit of statins on cancer prognosis, for example, prostate carcinoma. We found novel anti-tumor GSL antibodies circulating in 3/5 statin-treated, but not untreated, prostate cancer patients. Lowering tumor membrane cholesterol may permit immune recognition of otherwise unavailable tumor-associated GSL carbohydrate, for more effective immunosurveillance and active/ passive immunotherapy. Our results show standard immunodetection of tumor GSLs significantly under assesses tumor membrane GSL content, impinging on the current use of such antigens as cancer vaccines.
Introduction
Neoplastic-dependent changes in glycosphingolipid (GSL) synthesis have been well documented (Hakomori 2002; Prinetti et al. 2011) . Studies showing the expression of specific GSL antigens during embryogenesis (Andrews 1987 ) defined stagespecific embryonic antigens (SSEA-1 to -4). These antigens were found in tumors (Damjanov et al. 1982; Liebert et al. 1987) . Indeed, these GSLs are markers of normal (Gang et al. 2007 ) and cancer stem cells (Scaffidi and Misteli 2011; Gupta et al. 2012) , and used for their identification and isolation ). Such tumor-associated GSLs provide targets for cancer immunotherapy (Heimburg-Molinaro et al. 2011) .
Membrane GSLs and cholesterol can form a complex considered the basis of their accumulation in asymmetric membrane domains, termed "lipid rafts" (Lingwood and Simons 2010) . These domains are more ordered and accumulate proteins involved in signal transduction (Levental et al. 2010) , such that membrane rafts become foci for bio-information transit. GSLs within such domains can mediate transmembrane signaling (Iwabuchi et al. 2000) , and modulate signal transduction of other receptor proteins via lateral association (Kabayama et al. 2007 ). These domains are increased (Li et al. 2006 ) and key in the aberrant signaling and adhesion of cancer cells (Staubach and Hanisch 2011) .
Membrane GSL function is affected by its lipid structure (aglycone modulation (Lingwood 1996) ). The GSL carbohydrate conformation can vary as a function of the membrane microenvironment. Nine minimum energy conformers are described (Nyholm and Pascher 1993) . The interaction of the sterol hydroxyl with the amino function and anomeric oxygen of the GSL sugar within a GSL-cholesterol complex alters the carbohydrate conformation, from perpendicular to membrane parallel . This partially explains aglycone regulation of function (Lingwood 1996) and potentially impinges many aspects of GSL function. In the membrane parallel format, availability for exogenous ligand binding is restricted but lateral membrane interaction may be facilitated (Yahi et al. 2010) . Membrane perpendicular GSL carbohydrate optimizes extracellular trans interactions. These potentially cis and trans interacting conformers may encase a spectrum of GSL carbohydrate membrane display. In model membranes, the radial GSL carbohydrate dimension was inversely related to the cholesterol concentration , indicating potential intermediate carbohydrate conformers. Cholesterol masking separates (at least) two membrane pools of GSLs. The cholesterol-complexed, ligand-unavailable fraction can be larger (Mahfoud et al. 2010) .
Owing to increased rafts, cholesterol masking of (tumorassociated) GSLs may be greater in neoplastic, compared with normal cells, helping tumors evade immune surveillance.
Inhibitors of cholesterol biosynthesis (statins), administered to reduce serum cholesterol levels to prevent adverse cardiac events, result in a benefit to cancer patients ) of unknown precise etiology. Prostate (Marcella et al. 2011) , breast (Ahern et al. 2011) , ovarian (Elmore et al. 2008) and colorectal (Broughton et al. 2012) carcinoma patients have been shown by epidemiological analysis, to derive clinical benefits. To address whether statin therapy potentially results in the exposure of cholesterol-masked tumor cell GSL antigens, we examined the immunodetection of tumor-associated GSLs (Table I) , in human tumor biopsies before and after β-methylcyclodextrin (MCD)-mediated cholesterol depletion. These studies show that cholesterol masking of GSL tumor antigens is variable but pervasive in human primary carcinomas and suggests that statin-mediated GSL unmasking provides an effective means to promote cancer immunotherapy.
Results
The tumor-associated GSLs and the ligands used in these immunohistochemical studies are given in Table I . Three Mab anti-GSLs show minor cross-reactivity to related GSLs as detailed in each reference. Verotoxin1 (VT1) only binds globotriaosyl ceramide (Gb 3 ).
Unmasking tumor Gb 3 VT1 B binding is the most effective means of detecting cell membrane Gb 3 (Kim et al. 2011) . We used VT1 B binding to screen tumor biopsies for potential effect of cholesterol depletion on Gb 3 exposure. Figure 1aA shows binding to an ovarian carcinoma, a potential target for VT1-based antineoplastic treatment (Arab et al. 1997 ). Significant Gb 3 was detected in the unextracted section, as expected. However, following cholesterol extraction of a serial section, Gb 3 detection in this epithelial carcinoma was significantly increased. Initially, stained cells became more intensely labeled and previously unreactive cells became highly VT1B reactive, such that, essentially, all tumor cells were now reactive. Breast tumors upregulate Gb 3 (Johansson et al. 2009 ) and Gb 3 is a marker of breast cancer stem cells (Gupta et al. 2012) . In breast carcinoma (Figure 1aB ), ducts became more extensively/intensively VT1B reactive after cholesterol depletion. Small blood vessels also became more intensely and frequently VT1B detected. Pheochromocytoma is a rare, highly vascular adrenal tumor. Without extraction, this tumor is VT1B unreactive (Figure 1aC ). However, after MCD extraction, the characteristic infiltrating neomicrovasculature became significantly VT1B positive (Figure 1aC ). In a prostate tumor, ducts and their contents ( Figure 1aD ) and some small blood vessel endothelia were labeled (Figure 1aE ). Following cholesterol extraction, many more blood vessels became VT1B reactive ( Figure 1aD ) and the limiting membrane of some ducts, initially VT1B negative, became intensely VT1B reactive (Figure 1aD , E). In a testicular Leydig cell tumor, blood vessels within this initially virtually Gb 3 -negative tumor became highly VT1B reactive after cholesterol extraction (Figure 1aF) . Similarly, neuroblastoma is largely Gb 3 negative but major VT1 B staining of the tumor neovasculature and stromal tissue was induced by cholesterol depletion (Figure 1aG ). In contrast, VT1B blood vessel staining in a ganglioneuroma was virtually unaffected after MCD-cholesterol extraction (Figure 1aH ).
Colon carcinoma upregulates Gb 3 content (Distler et al. 2009 ) to provide a target for VT-based therapy. While some colon carcinomas were initially variably VT1B reactive, reactivity was markedly increased and "Gb 3 negative" tumors became highly VT1B reactive after cholesterol depletion (Figure 1b ). Unmasked Gb 3 was largely in the intercalated neovascular and associated stromal tissue, rather than the tumor cells per se.
In most tumors, cholera toxin binding to GM1 ganglioside was extensive and also enhanced following cholesterol depletion (Supplementary data, Figures S1 and S2).
Unmasking tumor GSLs SSEA-4 was immunodetected in all pheochromocytoma cells (Figure 2aA ). These adrenal chromaffin cell-derived, anti-SSEA-4-stained tumor cells were large and spherical. Staining in some cells was nonuniform. After serial section MCD-cholesterol extraction, the spherical cells were less anti-SSEA-4 reactive and NeuNAc α2-3Galβ1-3GalNAcβ1-3Galα1-4Galβ1-4Glcβ1-Cer MC-813-70 GM1b, GD1a Kannagi et al. (1983) 
No cross-reactivity Huang et al. (2006) Cholesterol-masked glycolipid antigens in human tumors a previously largely undetected, stellate cell population was stained (Figure 2aA , arrows). These may be sustentacular cells, a malignancy marker in this tumor (Unger et al. 1991 ). Anti-SSEA-4-stained duct-like structures of breast carcinoma were increased after cholesterol depletion (Figure 2aB , arrows). Other tumor-associated GSL antigens, SSEA-1 and SSEA-3, were not found but anti-globo H showed ductselective breast tumor staining unaltered by cholesterol depletion (not shown).
Anti-SSEA-4 staining of duct structures in prostate cancer was unaffected by cholesterol depletion (not shown), but anti-globo H staining of such structures was increased (Figure 2aC , arrows). Anti-SSEA-1 staining of the limiting cell layer of such ducts was remarkably enhanced following cholesterol extraction ( Figure 2aD ). Anti-SSEA-1 staining of the duct lumen was also significantly increased. Anti-SSEA-3 staining of prostate carcinoma was most extensively increased after cholesterol depletion (Figure 2aE ), such that initial duct-restricted detection was Anti-SSEA-1 staining of colon carcinoma was heterogeneous, as previously reported (Shi et al. 1984) . Anti-SSEA-1 staining was tumor cell specific and widespread in some samples (Figure 2bA and C) , but more restricted in others (Figure 2bB and D). Tumor cell anti-SSEA-1 staining of all samples was significantly increased after cholesterol depletion (Figure 2b) .
The increases in tumor-associated GSL immunodetection in the cancer biopsies studied are summarized in Table II . It is clear that while detection of most GSLs is increased, this is not a generalized increase. Some GSL antigens within the same (serial) sections are unaffected when large changes in others are seen.
Tumor GSL unmasking is related to nonuniform membrane cholesterol distribution To confirm GSL unmasking by MCD is cholesterol dependent, we compared tumor section VT1B-Gb 3 staining with that of filipin, before/after MCD extraction (Figure 3 ). Using prostate tumor sections, we defined neovasculature with differential VT1B staining (Figure 3a , three arrows), in relation to the cholesterol present in these same vessels, determined by filipin double labeling of the section, in which the sections were first labeled with VT1B (Figure 3a-d) . Of the three vessels arrowed, the central vessel is strongly stained by VT1B and contains no detectable cholesterol (Figure 3b ). VT1B staining of this vessel is unaffected by MCD (Figure 3c ). The vessel to the right is less intensely VT1B stained (Figure 3a) , contains cholesterol ( Figure 3b ) and VT1B staining is increased after MCD extraction (Figure 3c ), when cholesterol is removed (Figure 3d ). The vessel arrowed to the left is VT1B stained (Figure 3a) , contains significant cholesterol (Figure 3b ) and VT1B staining is greatly increased following cholesterol removal (Figure 3c ). The arrowhead in each panel (Figure 3a and b) shows a vessel in which VT1B staining is restricted to the cholesterol-low luminal area encompassed by a VT1B negative, cholesterolcontaining membrane. This membrane and some surrounding VT1B negative, high-cholesterol areas become highly VT reactive after MCD extraction (Figure 3c ).
Thus for Gb 3 containing membranes without cholesterol, MCD has no effect on VT1B-membrane Gb 3 staining, and for Gb 3 containing membranes with cholesterol, MCD increases VT1B staining as an approximate function of the original cholesterol content.
In this double-labeling study, the order in which the primary ligands were added was important. Adding filipin before VT1B increased VT1B staining compared with when VT1B was added first (Figure 3e c.f. 3a) but filipin staining was reduced when added first, compared with when VT1B was added first (Figure 3f c.f. 3b). This suggests that filipin binding to cholesterol can reduce cholesterol masking of Gb 3 for VT1B recognition and VT1B-binding Gb 3 may increase cholesterol availability for filipin binding.
Unique anti-tumor GSL antibodies in serum of prostate cancer patients on statin therapy Prostate cancer is the neoplasia most frequently associated with benefit from statin treatment (Marcella et al. 2011) . Moreover, prostate tumor-specific gangliosides (Ravindranath et al. 2004 ) and a GSL from a metastatic prostate cancer cell line (Zhang et al. 2010) have been proposed as an effective immunogen against this cancer. We, therefore, compared sera from a small cohort of prostate cancer patients who were, or were not, on statin therapy for antibody binding to PC-3 metastatic prostate cancer cell GSLs by thin-layer chromatography (TLC) overlay (Figure 4 ). While some binding to one GSL was observed for all samples, in 3/5 statin samples, a significant antibody binding to two additional PC-3 prostate tumor GSLs was seen. The retardation factors of these species are consistent with ceramide tetra and penta hexosides. The variable effect of 56°C pretreatment, used to enhance autoantibody detection (Abu-Shakra and Shoenfeld 2007; Cheng and Chamley 2008), indicates a compound phenotype, but no reactivity against these species was detected for sera from five non-statin-treated prostate cancer patients.
Discussion
The aberrant tumor metabolism of cholesterol is proving a valid cancer chemotherapeutic target, based on lipid raft transmembrane signaling (Gorin et al. 2012 ). Our studies identify a new mechanism by which cholesterol might aid tumor progression.
Cholesterol changes membrane GSL presentation
Although the sphingolipid/cholesterol association mediates the increased order of lipid rafts (Simons and Sampaio 2011) , cholesterol fluidizes sphingolipid model membranes (Simons and Vaz 2004) . The cholesterol-induced change in GSL carbohydrate is both permitted by, and causes, this increased fluidity. Cancer cell membranes have increased fluidity (Zeisig et al. 2007 ) and increased cholesterol-containing lipid rafts (Li et al. 2006) relative to normal cells. Cholesterol/GSLs accumulate in membrane rafts, foci for transmembrane signaling (Suzuki 2012 ) and intercellular communication (Defamie and Mesnil 2012) . Interaction of GSLs and cholesterol forms a molecular complex in which the membrane surface located sterol hydroxyl forms an H-bond complex with the sphingoid base and the anomeric GSL oxygen, such that the carbohydrate becomes membrane parallel and the steroid hydroxyl is concomitantly protected from unfavorable hydrophobic interaction-"umbrella effect" ). This conformational change can restrict ligand access to membrane GSL carbohydrate and, as a result, two pools of plasma membrane GSL exist (Mahfoud et al. 2010) , of which the cholesterol-complexed, exogenous While all sera showed some common reactivity to one species (asterisk), 3/5 sera from patients on statin treatment showed reactivity to two additional PC-3 cell GSLs (arrows) compared with non-statin-treated patient sera. Data for untreated sera are shown, except for Lane 2, which was increased by 56°C pretreatment. Binding in Lane 4 was reduced after 56°C pretreatment.
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ligand-undetected ("invisible") fraction may be greater. Cholesterol/GSL masking depends on the radius of membrane curvature (Mahfoud et al. 2010) . High membrane curvature may counter GSL masking. In addition, in model membrane studies, inclusion of specific GSL monohexosides could "rescue" GSLs from cholesterol masking (Mahfoud et al. 2010) , indicating that neighboring GSLs can modulate cholesterol masking of a particular GSL. This provides an unappreciated means for the regulation of cell membrane GSL receptor function which tumor cells may use to advantage to avoid immunodetection. Filipin section staining showed that membrane cholesterol is highly asymmetrically distributed within the tumor cell population. MCD unmasking of GSL is a direct function of the original cholesterol content of the cell membrane-we show greatest unmasking for membranes with the highest cholesterol content and no change in GSL immunodetection for membranes lacking cholesterol. In some cases, no GSL staining is observed prior to cholesterol extraction, but this did not correlate with initial high membrane cholesterol content. This is a newly discovered component of the close functional association of sphingolipids and steroids, and its extent and regulation have yet to be defined. The membrane GSL "umbrella" may restrict filipin binding to cholesterol. Prior VT1B binding increased filipin staining, whereas prior filipin binding increased VT1B staining. This suggests that the membrane GSL-cholesterol complex equilibrium may be moved to the left by either ligand binding. Binding cholesterol, in addition to its depletion, may free membrane GSL for ligand binding. The GSL-cholesterol interaction may provide a dynamic means to restrict membrane cholesterol bioavailability, generating a new mechanism whereby the binding of one ligand to its receptor enhances another ligand-receptor binding. The abnormal cholesterol of cancer cell membranes (Li et al. 2006) provides the opportunity to subvert this mechanism to regulate cell surface GSL function to advantage and restrict immune recognition of tumor-associated GSLs. Although heterogeneously expressed, increased cholesterol may be associated with increased tumor aggressiveness (Llaverias et al. 2011 ) and tumor grade (Shafique et al. 2012) . Cholesterol masking of membrane GSL is potentially a general regulator of membrane GSL receptor function, e.g., in host/microbial pathology (Khan et al. 2009; Rondy et al. 2011) , immunity and autoimmune disease (Miyake and Yamamura 2005; Park et al. 2005) , and also normal GSL physiology, e.g., in neuronal function (Schengrund et al. 2012 ).
Can cholesterol restrict antibody binding to cancer cell GSLs?
Tumor evasion of immune response is key to cancer progression, in which many processes combine (Stewart and Abrams 2008) . Tumor-associated GSLs are structurally well defined and promoted as immunotherapeutic targets (Wang et al. 2008; Zhu et al. 2009; Heimburg-Molinaro et al. 2011) . Our finding that cholesterol can mask membrane GSLs to prevent ligand binding which can be reversed in part, by cholesterol depletion, and the fact that that tumor cell membrane cholesterol rafts are increased, led to our postulation that immune recognition of tumor GSLs might be hindered by cholesterol/GSL masking. Our present primary tumor immunohistochemistry confirms that some tumor-associated GSL antigens are present but only become available for antibody binding after cholesterol depletion.
Cholesterol-enriched lipid rafts are important in lymphocyte activation (Kabouridis 2006 ) and cholesterol depletion might affect immune surveillance. However, cholesterol reduction can augment (Mahammad et al. 2010) or benefit T-cell activation (Surls et al. 2012) , suggesting that judicial tumor cholesterol reduction and immunosurveillance are not incompatible.
Of the tumor-associated GSL antigens tested, all showed evidence of cholesterol masking depending on tumor sample, but not every GSL tested in a given tumor showed evidence of cholesterol masking. Thus, GSL masking by cholesterol must be regulated.
Our pilot study detecting antibodies to prostate tumor cell GSLs in some sera from prostate cancer patients undergoing statin therapy is consistent with cholesterol restricting tumor GSL immunogenicity. The significance of this initial trend needs to be confirmed in a larger patient cohort and the identity of the target GSLs defined. The bound species correspond to a four and a five sugar GSL, but the reactive GSL could be a minor species. Since a monoclonal antibody to a PC-3 prostate tumor cell line GSL (as yet uncharacterized) can protect against prostate tumor growth (Zhang et al. 2010) , the circulation of "anti-PC-3 GSL" antibodies could be of benefit.
Gb 3 binding was increased for most tumors tested. Verotoxin binding to tumor and neovascular Gb 3 has been proposed as a cancer therapy (Lingwood 2000; Johannes and Romer 2010; Engedal et al. 2011) . Prior cholesterol reduction might increase the efficacy/scope of this approach.
The GSL tumor antigens we have unmasked, for example, SSEA-3 in prostate cancer, SSEA-4 in pheochromocytoma, SSEA-1 in colon carcinoma (Shi et al. 1984) , represent tumorassociated GSL antigen candidates for immunotherapy/ immunosurveillance and could relate to the beneficial effect of statins in cancer prognosis Gutt et al. 2010; Ahern et al. 2011; Broughton et al. 2012) , although the pleiotropic effects of statins allow other explanations (Palaniswamy et al. 2010) . Antibodies raised by neoplastic GSL carbohydrate immunogens (Fragaki et al. 2012) or their peptide mimics (Pashov et al. 2007; Marmot et al. 2012) , should be more effective against cholesterol deficient tumors.
Our results showing that cholesterol depletion remarkably enhances antibody binding to tumor-associated GSLs antigens and that the antigens "exposed or unmasked" vary between tumor types, provide both a new specific approach in terms of cancer vaccines, but also potentially a more generalized basis for promoting overall immune control of cancer and "pre-cancer" cells. Low-affinity IgM anticarbohydrate antibodies can be sufficient for effective tumor regression (Marmot et al. 2012) . Depletion of tumor plasma membrane cholesterol may provide the means to achieve this goal.
The widespread problem of cancer over diagnosis (Welch and Black 2010; Marmot et al. 2012 ) as a function of tumor screening could be explained by the autoregression, perhaps due to effective early stage immunosurveillance, of non-progressing tumor subsets. We would consider tumor cell membrane cholesterol levels, and therefore patient cholesterol metabolism, as a variable risk factor in determining the likelihood of such an event.
Materials and methods
The study was approved by the Research Ethics Board of the Research Institute, Hospital for Sick Children.
Tissue staining
Frozen tumor tissues were obtained from the Department of Pediatric Laboratory Medicine at this hospital and the Ontario Institute for Cancer Research Tumor Bank (Toronto, Ont, Canada). Cryosections (6 μm) were dried and fixed with 4% paraformaldehyde in phosphate-buffered saline (PBS) for 10 min then treated ±10 mM MCD in PBS for 30 min at room temperature (RT). Under these conditions, MCD selectively extracts cholesterol , and negative section staining with filipin (see below) was routinely observed.
For brightfield microscopy of sections stained with horseradish peroxidase (HRP)-conjugated secondary antibodies, endogenous peroxidase blocker (Universal Block, KPL, Inc., Gaithersburg, MD) was added for 20 min, then samples were blocked with 1% normal goat serum (NGS) in PBS (1% NGS) for 20 min. Sections were treated with primary antibodies or toxins followed by antitoxin. All reagents were diluted in 1% NGS, and all toxin/antibody reactions were for 30 min. VT1-B subunit (1 μg/mL) was purified in our laboratory (Nutikka et al. 2003) . Cholera toxin B subunit (0.1 µg/mL) was from Sigma (St. Louis, MO, (C9903)). Toxin incubation was followed by rabbit polyclonal anti-VT1-B-6869 (Boyd et al. 1991) or polyclonal rabbit anti-CT (Sigma, St Louis, MO, C3062), respectively, both diluted 1:1000. Primary antibodies were mouse IgM monoclonal anti-SSEA-1 (clone MC-480), rat IgM monoclonal anti-SSEA-3 (clone MC-631) and mouse IgG monoclonal anti-SSEA-4 (clone MC-813-70); from Developmental Studies Hybridoma Bank, University of Iowa. Primary mouse IgM monoclonal anti-globo H was from Enzo Life Science (Farmingdale, NY) (clone MBr1, ALX-804-550). All primary antibodies were used at 2 μg/mL. Secondary antibodies conjugated to HRP were applied (1:500): HRP-goat anti-rabbit IgG (Bio-Rad, Hercules, CA, 170-6515), HRP-goat anti-mouse IgM (Jackson, ImmunoResearch, West Grove, PA, 115-035-020), HRP-mouse anti-rat IgM (Serotec, Raleigh, NC, MCA 189P) or HRP-goat anti-mouse IgG (Bio-Rad, Hercules, CA, 170-6516). Sections were incubated for 5 min with peroxidase substrate (ImmPACT DAB, Vector Laboratories, Burlingame, CA). Nuclei were weakly counterstained with aqueous Mayer's hematoxylin (Vector Laboratories, Burlingame, CA). For hematoxylin/eosin staining, hematoxylin was used undiluted for 5 min followed by aqueous 0.5% Eosin Y (Sigma, St. Louis, MO, HT110216) for 1 min. Slides were dehydrated in ethanol, cleared with xylene and mounted in Permount (Fisher, Ottawa, Ont, Canada). Images were recorded with a Nikon microscope (Eclipse E4000) using the Nikon ACT-1 software, version 2.70. Quantification was performed on original digital images by differentiating color threshold values using the PerkinElmer Volocity 6.2.1 software. The receptor stain pixels were expressed as a function of total image pixels.
For fluorescence microscopy of filipin-stained sections, filipin III (Sigma, St Louis, MO, F4767) was dissolved in dimethyl sulfoxide/PBS (1:4) (50 μg/mL) and added to sections for 30 min. After rinsing, slides were mounted in aqueous fluorescent-mounting medium (DakoCytomation, Glostrup, Denmark). Images were recorded with a Leica microscope (DMI 6000 B) using the LA SAF software, version 2.2.1.
For double staining, sections were stained with filipin and toxin/ antibodies. When filipin was used first, it was followed by toxin/ primary antibody, then HRP-conjugated secondary antibodies. When toxin/antibody was reacted first, filipin was added after the HRP-conjugated secondary antibody, followed by incubation with the peroxidase substrate and counterstain. All incubations were at RT. Slides were mounted in the aqueous fluorescent-mounting medium and recorded with the Leica microscope.
To confirm the detection of GSL antigens only, sample tumor frozen sections were subject to 10 min MeOH and 10 min MeOH/ CHCl 3 1:1 extraction prior to antibody or VTB staining. This resulted in almost complete loss of tissue staining (Supplementary data, Figure S1 ). These samples were not pretreated with paraformaldehyde since cross-linked proteins may entrap lipids.
TLC overlay
A total lipid extract from the metastatic prostate cell line PC-3 was prepared: 15 × 10 6 cells were scraped, washed and pelleted in PBS then vortexed in 250 µL of dH 2 O. To this was added 7.5 mL of chloroform/methanol (C/M) 2:1 and the mixture was shaken for 3 h, then filtered through glass wool, which was washed with C/M 2:1 and the filtrate was dried under nitrogen. The residue was saponified in 500 µL of 0.5 N NaOH in methanol (MeOH) for 1 h at 37°C. The mixture was neutralized with 500 µL of 0.1 M ammonium acetate in MeOH, followed by 370 µL of 0.5 M HCl, then 4 mL of dH 2 O. A C18 cartridge was prepared in MeOH, then 10% MeOH/H 2 O. The saponified lipid was added and the C18 cartridge was washed with 10% MeOH/H 2 O. The lipids were eluted with 5 mL of MeOH then 3 mL of C/M 2:1 and dried under nitrogen and the resulting residue of total lipid extract was dissolved in C/M 2:1 and amounts corresponding to 5 × 10 5 cells were applied to TLC plates which were run in C/M/H 2 O, 60/35/8. Lanes were cut and blocked in 50 mM Tris-HCl, pH 7.2, with 0.15 M NaCl and 1% bovine serum albumin (TBS/BSA). Blinded serum samples were from the Genitourinary BioBank at Princess Margaret Hospital, Toronto, from prostate cancer patients, five taking statins and five who were not. Sera were diluted 10-fold in TBS/BSA and tested before and after I h 56°C pretreatment (Cheng and Chamley 2008) . TLC strips were incubated overnight at 4°C with sera then washed 3× with Tris/BSA. The strips were incubated for 1 h at RT with secondary antibodies conjugated to HRP diluted in TBS/BSA (1:500): HRP-goat anti-human IgG (Sigma, A6029) and HRP-goat anti-human IgM (Bio-Rad, 172-1035) together. They were then washed 3× in TBS/BSA, 2× in TBS and once in dH 2 O, then incubated with peroxidase substrate (ImmPACT DAB) for 10 min. Color development (indicating IgG and/or IgM binding; anticarbohydrate antibodies are usually IgM) was stopped by washing in TBS. Chromatograms were dried and scanned. GSL standards were detected with orcinol reagent.
Supplementary data
Supplementary data for this article is available online at http:// glycob.oxfordjournals.org/.
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